MDMA-assisted therapy training is currently offered through MAPS PBC's Public Benefit training program, Polaris Insight, CIIS's Certificate in Psychedelic-Assisted Therapies, and Fluence's MDMA modules. A clinical license is required — no lay pathway exists. Cohorts are 100–200 hours, $8,000–$14,000.
MDMA-assisted therapy is not yet FDA-approved, but training programs are actively running in 2026. This guide maps the current MDMA-therapy training providers, prerequisites, costs, and what happens to trained clinicians when MDMA does receive approval.
To train as an MDMA therapist, hold an active clinical license, then complete a MAPS PBC, CIIS, Polaris Insight, or Fluence MDMA training module. There is no lay pathway. Training runs 6 months to 1 year and costs $3,000 to $15,000. Because MDMA is not yet FDA-approved, most trained clinicians are in a waiting posture — expanded-access, VA-affiliated studies, and REMS-network readiness are the main placements in 2026.
The umbrella guide at /guides/how-to-become-a-psychedelic-therapist lists training providers by name and compares psychedelic-therapy career paths across substances. This page maps the MDMA-specific training tracks in detail — MAPS PBC, Polaris Insight, CIIS, and Fluence — with cost, hours, and post-training placement per program.
Three points make MDMA training distinctive right now:
MDMA is a Schedule I controlled substance and is not FDA-approved as of mid-2026. In August 2024 the FDA issued a Complete Response Letter on the MAPS PBC New Drug Application, asking for additional data. MAPS PBC has restructured and continues to work toward resubmission.
Legal MDMA-assisted therapy in the US in 2026 exists only in three settings:
MAPS PBC runs the reference training program for MDMA-assisted therapy. The program trained the clinicians who delivered the Phase 3 trials and set the manual all other programs teach from.
An active clinical license (MD, DO, NP, PA, psychologist, LCSW, LPC, MFT) or a supervised trainee status. MAPS PBC has historically prioritized clinicians with trauma-specialty backgrounds.
Roughly 6 to 12 months across online coursework, in-person intensives, and supervised role-play. Cohort openings have been limited since the 2024 CRL. Monitor MAPS.org for reopened enrollment.
Program cost has varied by cohort. Historical tuition ran $8,000 to $12,000. Confirm current tuition directly with MAPS PBC.
Polaris Insight Center offers MDMA-therapy modules that build on their KAP training foundation. This is a good option for clinicians who already completed KAP training and want to add MDMA readiness.
Modules typically cover MDMA pharmacology, trauma-focused protocols, and the inner-directive approach used in MAPS trials. Cost runs roughly $3,000 to $5,000 depending on module bundle. Prerequisites: active clinical license, prior KAP training recommended.
The California Institute of Integral Studies (CIIS) Certificate in Psychedelic-Assisted Therapies and Research is the main academic option for MDMA training. It covers MDMA, psilocybin, and ketamine in a single 9-month curriculum.
Cost is roughly $10,000. Prerequisites include a master's degree in a mental health field or equivalent clinical experience. CIIS is a regionally accredited graduate institution, which gives the certificate weight with employers and boards.
Fluence runs MDMA-focused modules within its broader psychedelic-therapy curriculum. These modules cover MDMA pharmacology, trauma protocols, and integration.
Cost runs $3,000 to $7,000 depending on the bundle. Prerequisites: active clinical license. Fluence is largely online with periodic in-person intensives.
| Program | Approx. cost | Hours | Format | Prerequisites | MAPS-endorsed? |
|---|---|---|---|---|---|
| MAPS PBC MDMA Training | ~$8,000–$12,000 | ~200 hours | Hybrid (online + intensives) | Clinical license | Yes (in-house) |
| CIIS Certificate | ~$10,000 | ~9 months, ~200 hours | Hybrid | Master's in mental health | Aligned; not formally endorsed |
| Polaris Insight MDMA modules | ~$3,000–$5,000 | ~40–80 hours | Hybrid (SF retreat) | Clinical license; KAP recommended | Aligned with MAPS manual |
| Fluence MDMA modules | ~$3,000–$7,000 | ~60–120 hours | Mostly online | Clinical license | Aligned; not formally endorsed |
Post-training placement in 2026 is limited by MDMA's Schedule I status. Three legal pathways exist today.
MAPS PBC has historically offered a small number of sponsored roles for trained clinicians. Slots have been limited since the 2024 CRL. This remains the closest thing to a direct pipeline into MDMA work.
A handful of expanded-access and Phase 3 trial sites hire trained clinicians. Check ClinicalTrials.gov via our tool for open MDMA studies.
The VA has invested in MDMA research at select facilities. Clinicians already inside the VA system are best positioned. Outside hires happen but are competitive.
When MDMA is FDA-approved, distribution will almost certainly go through a Risk Evaluation and Mitigation Strategy (REMS) program — the same model used for esketamine (Spravato). Only clinicians in the REMS network will be able to administer MDMA. Prior training is the entry ticket into the REMS network.
Existing MAPS-trained therapists are expected to be first hires when approval lands. CIIS, Polaris, and Fluence graduates will follow as REMS capacity expands. This is why many clinicians train now despite approval uncertainty.
Total cost of MDMA training runs $3,000 to $15,000, depending on program depth. Total timeline is 6 to 12 months for most programs, or up to 2 years if combined with a full graduate certificate at CIIS.
Add malpractice review to your planning. Not every carrier underwrites psychedelic therapy work. Confirm coverage before enrolling.
Get MDMA research & policy updates
New trials, FDA decisions, and legal changes for MDMA — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.